KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Revenue (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Revenue for 7 consecutive years, with $622.0 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 4.78% to $622.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.4 billion through Dec 2025, up 5.06% year-over-year, with the annual reading at $2.4 billion for FY2025, 5.06% up from the prior year.
  • Revenue hit $622.0 million in Q4 2025 for Royalty Pharma, up from $609.3 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $684.0 million in Q1 2023 to a low of $536.0 million in Q2 2022.
  • Historically, Revenue has averaged $576.2 million across 5 years, with a median of $570.6 million in 2021.
  • Biggest five-year swings in Revenue: rose 21.69% in 2023 and later fell 16.96% in 2024.
  • Year by year, Revenue stood at $575.7 million in 2021, then dropped by 1.73% to $565.7 million in 2022, then grew by 5.36% to $596.1 million in 2023, then dropped by 0.41% to $593.6 million in 2024, then increased by 4.78% to $622.0 million in 2025.
  • Business Quant data shows Revenue for RPRX at $622.0 million in Q4 2025, $609.3 million in Q3 2025, and $578.7 million in Q2 2025.